Pear Therapeutics
The company made collaboration agreements with Empatica and etectRx, and a licensing deal with KeyWise.
The investment from "a leading national Integrated Delivery Network" brings the Series D's total to $100 million.
MobiHealthNews spoke with Pear Therapeutics, Click Therapeutics and DTx newcomer Mahana Therapeutics to discuss whether in-licensing is the way to go for those just entering the space.
Flare Capital's Alexandra Mullin and Ian Chiang outline COVID-19's impact on the worsening opioid crisis and how the digital opioid use disorder space is likely to develop over the coming years.
The pair will meet quarterly to discuss possible integrations and collaborations with the pharma industry.
The results will not impact the current rollout of a new version of the app, under special FDA guidelines.
It's been quite a year for digital, from Akili's de novo clearance to the downfall of 'digital pill' maker Proteus. MobiHealthNews takes a look back at the highlights.
The study, backed by the digital therapeutics company, measured the change in clinical encounter frequency among opioid use disorder patients who were also prescribed buprenorphine.
The new analysis of a Pear Therapeutics-based randomized controlled trial came alongside another investigation that spotted early signs of treatment dropout.
Also: Google promises not to use Fitbit data for targeted advertising; Renalytix AI details its international IPO; New food tracking app relies on machine learning.